CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis (NCT07207811)
CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
🩺 Plain-English Summary (8th-Grade Level)
This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Hospital — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (295 Sites)
Showing the first 25 of 295 sites.
- Mayo Clinic Hospital — Phoenix, Arizona
- University of California San Diego (UCSD) - Sulpizio Cardiovascular Center (SCVC) — La Jolla, California
- Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII) — Los Angeles, California
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California
- UCI Medical Center — Orange, California
- Profound Research LLC at Southern California Heart Specialists — Pasadena, California
- University of California, San Francisco Medical Center — San Francisco, California
- NorthBay Clinical Research — Santa Rosa, California
- Lucile Packard Children's Hospital — Stanford, California
- Yale University School of Medicine — New Haven, Connecticut
- MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center — Washington D.C., District of Columbia
- UF Health Heart and Vascular Hospital — Gainesville, Florida
- Northeast Georgia Heart Center, Pc (Nghc) — Gainesville, Georgia
- The Queen's Medical Center — Honolulu, Hawaii
- Northwestern University Clinical and Translational Sciences Institute — Chicago, Illinois
- The University of Chicago Medicine — Chicago, Illinois
- Endeavor Health - Glenbrook Hospital — Glenview, Illinois
- Indiana University (IU) Health - Methodist Professional Center II — Indianapolis, Indiana
- LCMC - LSU University Medical Center New Orleans LCMC Center — New Orleans, Louisiana
- University of Maryland Medical Center (UMMC) - Children's Hospital (UMCH) — Baltimore, Maryland
- John Hopkins Medicine — Baltimore, Maryland
- Tufts Medical Center — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan Health System — Ann Arbor, Michigan
- Henry Ford Health — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (866) 867-7178
Email: clinicaltrials@novonordisk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Explore by condition: All Transthyretin Amyloid Cardiomyopathy (ATTR CM) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.